RareMed Solutions announced on September 2, 2025, an expansion of its relationship with PTC Therapeutics, launching non-commercial pharmacy dispensing services for PTC's therapy, Sephience. This expansion aims to enhance patient access to the newly approved treatment for phenylketonuria (PKU).
The collaboration follows the recent FDA approval of Sephience for adult and pediatric patients with PKU. RareMed Solutions specializes in providing patient support services for complex therapies, ensuring efficient delivery of critical medications.
This partnership is a strategic move to support the commercial rollout of Sephience, facilitating its availability to patients across the United States. It underscores PTC Therapeutics' commitment to ensuring comprehensive access to its innovative rare disease treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.